Tagged Articles

hypoglycemia 11 articles

Diabetes test strips recalled due to labeling error

Diabetic Supply of Suncoast, Inc. has issued a recall of all BMB-BA006A Advocate Redi-Code+ test strips manufactured by BraodMaster Bio-Tech Corp due to a labeling error that could cause confusion about which meter models the test strips can work with. This is the third recall of diabetic test strips in the past year. In the affected Suncoast lots, the test strip model code (BMB-BA006A) was omitted. Suncoast issued the recall to avoid confusion and the possible misuse of the test strips with the wrong blood glucose meter. Using the test strips with the wrong meters can cause false readings. Falsely ... Read More

Nova diabetes test strips recalled

Several lots of Nova Max Glucose Test Strips used to test blood sugar levels  are being recalled because they may report a false, abnormally high blood glucose result. This defect could, under certain conditions, result in an insulin dosing error that could lead to serious health risks requiring immediate medical attention. The recall, initiated by Nova Diabetes Care, affects 21 lots of Nova Max Glucose Test Strips and Nova Max Plus glucose meter kits that include the test strips. The affected products were distributed both within and outside the continental USA. Nova Diabetes Care has notified all registered users, health ... Read More

Medtronic issues urgent medical device safety notice regarding infusion pumps

Medtronic has issued an urgent medical device safety notification to patients and health care providers regarding its Paradigm Infusion Set Connectors, which connect to Medtronic Paradigm infusion sets used to administer insulin to diabetic patients in order to maintain blood glucose levels. Vents can become blocked if insulin or other fluids come in contact with the inside of the connector on the Medtronic Paradigm infusion sets. If the pump’s vents are blocked, this can potentially result in too much or too little insulin being delivered, which may cause hypoglycemia or hyperglycemia. In extreme cases, these conditions may cause loss of consciousness or death. According to the safety notification, ... Read More

Diabetes organizations broaden definition of hypoglycemia to better serve patients

The Endocrine Society and the American Diabetes Association broadened the definition of hypoglycemia to include events during which a diabetic experiences symptoms consistent with low blood sugar without a supporting blood test. Hypoglycemia occurs when a person has low blood glucose concentrations that puts him at risk for injury or death. Acute hypoglycemia can cause confusion, loss of consciousness and seizures. The definition of hypoglycemia was broadened because experts noted that episodes of hypoglycemia can occur even when blood tests show glucose levels are in the normal range. The organizations also emphasized the importance of using hypoglycemic risk as one ... Read More

Diabetes infusion pumps recalled due to dangerous defect

Animas 2020 Insulin Pumps manufactured between March 1, 2012 and November 30, 2012, are being recalled because the devices have a defective component that may trigger the pumps to sound a false alarm or warning. The pumps are used to deliver insulin directly into the blood of diabetics. The recall is categorized as a Class 1, which is the most serious type of recall and involves situations in which there is a reasonable probability that using the products will cause serious adverse health consequences or death. The defect may signal the pump to warn of one of the following: “Loss ... Read More

FDA to review drugs in new class of type 2 diabetes medications

Two type 2 diabetes drugs in a new class of blood sugar lowering medications known as SGLT2 inhibitors are hoping to win approval from the Food and Drug Administration (FDA) – Johnson & Johnson’s canagliflozin, and empagliflozin, made jointly by Eli Lilly and Boehringer Ingelheim. The drug makers presented the benefits of their medications recently at the European Association for the Study of Diabetes meeting in Berlin. The two drugs are among several of their kind for the treatment of diabetes, and are in various stages of development. The FDA is currently reviewing data for canagliflozin, and it is expected ... Read More

Study shows daily insulin injections do not raise risk for heart attack, stroke, cancer

The safety of diabetes medications has been a concern since the Food and Drug Administration (FDA) issued warnings about cancer and heart attacks associated with the type 2 diabetes drugs Actos and Avandia. For decades, people have wondered if the use of another diabetes medication – insulin – made diabetics more susceptible to cardiovascular disease and cancer. But, a new study offers some peace of mind, indicating long-term, daily injections of insulin do not appear to increase the risk for heart attacks, strokes, or cancer in people with type 2 diabetes or pre-diabetes. The new international study, led by Canadian researchers, ... Read More

New diabetes drugs have to provide more proof they are safe

These days, drugs to treat diabetes have one of the highest safety standards to clear before they are granted approval by the Food and Drug Administration (FDA). Placebo-controlled studies are no longer enough to sway agency decision makers. Drug companies must prove their new diabetes treatments won’t cause more problems than the condition they are treating. Which is why excitement over promising data from phase II studies on LY2605541, a joint effort by Eli Lilly and Boehringer Ingelheim, is contained. The drug showed better or equal glycemic control for patients with type 1 or type 2 diabetes than other similar ... Read More

Diabetes drugs sent thousands to emergency room last year

Diabetes drugs such as Actos and Avandia are among the four categories of medications responsible for two-thirds of emergency room visits in people over the age of 65, according to a new study published in the New England Journal of Medicine. Other categories that have been found to cause problems include the blood thinner warfarin and oral anti-platlet drugs like Plavix, both of which are taken for heart disease. The study reviewed nearly 100,000 emergency hospitalizations for adverse drug reactions, such as allergic reactions, and found that many could have been avoided with proper medical follow-ups, monitoring and patient education. ... Read More

Doctors warned of risks with type 2 diabetes drug

Pharmaceuticals maker Novo Nordisk is reminding doctors that its type 2 diabetes injectable drug Victoza (liraglutide) can cause serious health problems and is part of a Risk Evaluation and Mitigation Strategy (REMS). REMS are required for newly or already approved prescription drugs in order to ensure the benefits of the drug outweigh the risks associated with it. Victoza is being evaluated to determine if it causes thyroid tumors, thyroid cancers and other serious illnesses. A recent assessment by Novo Nordisk found that some primary care providers may not be fully aware of the serious risks associated with Victoza. In studies ... Read More